Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

NCT04639986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

NCT07299409 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

NCT06926920 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

NCT04001634 ·Status: COMPLETED

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

NCT04595565 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Fulvestrant 500mg in Patients With Advanced Breast Cancer

NCT02909361 ·Status: UNKNOWN

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

NCT03084939 ·Status: COMPLETED ·Phase: PHASE3

Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients

NCT01658033 ·Status: COMPLETED ·Phase: PHASE2

Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients

NCT05839288 ·Status: COMPLETED

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

NCT04927884 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients

NCT03541863 ·Status: COMPLETED

Real World Study on the Efficacy and Safety of Anti-HER2 Therapy

NCT05367739 ·Status: COMPLETED

Sacituzumab Govitecan In TNBC

NCT04230109 ·Status: RECRUITING ·Phase: PHASE2

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

NCT05675579 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

NCT06344780 ·Status: ACTIVE_NOT_RECRUITING

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

NCT04263298 ·Status: RECRUITING ·Phase: PHASE3

Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment

NCT06914661 ·Status: ENROLLING_BY_INVITATION

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

NCT06210776 ·Status: RECRUITING

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

NCT06993506 ·Status: NOT_YET_RECRUITING

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

NCT05629949 ·Status: COMPLETED ·Phase: PHASE3

Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

NCT06341621 ·Status: RECRUITING ·Phase: PHASE3

Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer

NCT06578299 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

NCT05263570 ·Status: RECRUITING